中成药治疗慢性前列腺炎临床应用指南(2021年)

2022-05-12 《中成药治疗优势病种临床应用指南》标准化项目组 中国中西医结合杂志

慢性前列腺炎(chronic prostatitis,CP)一直是困扰泌尿男科医生的常见疾病,对患者的身心健康造成严重影响。国外研究显示CP发病率在10%~15%之间,国内报道CP发病率在6.0%~3

中文标题:

中成药治疗慢性前列腺炎临床应用指南(2021年)

发布日期:

2022-05-12

简要介绍:

慢性前列腺炎(chronic prostatitis,CP)一直是困扰泌尿男科医生的常见疾病,对患者的身心健康造成严重影响。国外研究显示CP发病率在10%~15%之间,国内报道CP发病率在6.0%~32.9%之间。

相关资料下载:
[AttachmentFileName(sort=1, fileName=中成药治疗慢性前列腺炎临床应用指南(2021年).pdf)] GetToolGuiderByIdResponse(projectId=1, id=bd0451c002a3e099, title=中成药治疗慢性前列腺炎临床应用指南(2021年), enTitle=, guiderFrom=中国中西医结合杂志, authorId=0, author=, summary=慢性前列腺炎(chronic prostatitis,CP)一直是困扰泌尿男科医生的常见疾病,对患者的身心健康造成严重影响。国外研究显示CP发病率在10%~15%之间,国内报道CP发病率在6.0%~3, cover=https://img.medsci.cn/20220513/1652452132497_5579292.png, journalId=0, articlesId=null, associationId=2343, associationName=《中成药治疗优势病种临床应用指南》标准化项目组, associationIntro=《中成药治疗优势病种临床应用指南》标准化项目组, copyright=0, guiderPublishedTime=Thu May 12 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">慢性前列腺炎(chronic prostatitis,CP)一直是困扰泌尿男科医生的常见疾病,对患者的身心健康造成严重影响。国外研究显示CP发病率在10%~15%之间,国内报道CP发病率在6.0%~32.9%之间。</span></p>, tagList=[TagDto(tagId=300, tagName=泌尿外科), TagDto(tagId=303, tagName=慢性前列腺炎)], categoryList=[CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8260, appHits=95, showAppHits=0, pcHits=619, showPcHits=8158, likes=0, shares=16, comments=3, approvalStatus=1, publishedTime=Sat May 14 15:27:00 CST 2022, publishedTimeString=2022-05-12, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri May 13 22:31:37 CST 2022, updatedBy=6477789, updatedName=MS南菜园, updatedTime=Wed Jan 03 00:03:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中成药治疗慢性前列腺炎临床应用指南(2021年).pdf)])
中成药治疗慢性前列腺炎临床应用指南(2021年).pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2116283, encodeId=58b12116283f1, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Fri Feb 24 15:37:36 CST 2023, time=2023-02-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1220862, encodeId=47a6122086289, content=之前对中成药有偏见,现在学习了,很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cf78170543, createdName=ms5000000043316693, createdTime=Thu May 19 10:03:46 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220225, encodeId=940d122022529, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2f71997775, createdName=ayqdf, createdTime=Tue May 17 09:52:24 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2023-02-24 ms1000000439125996 来自广东省

    参考学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2116283, encodeId=58b12116283f1, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Fri Feb 24 15:37:36 CST 2023, time=2023-02-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1220862, encodeId=47a6122086289, content=之前对中成药有偏见,现在学习了,很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cf78170543, createdName=ms5000000043316693, createdTime=Thu May 19 10:03:46 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220225, encodeId=940d122022529, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2f71997775, createdName=ayqdf, createdTime=Tue May 17 09:52:24 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2022-05-19 ms5000000043316693

    之前对中成药有偏见,现在学习了,很好的资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2116283, encodeId=58b12116283f1, content=参考学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef68112305, createdName=ms1000000439125996, createdTime=Fri Feb 24 15:37:36 CST 2023, time=2023-02-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1220862, encodeId=47a6122086289, content=之前对中成药有偏见,现在学习了,很好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3cf78170543, createdName=ms5000000043316693, createdTime=Thu May 19 10:03:46 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220225, encodeId=940d122022529, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2f71997775, createdName=ayqdf, createdTime=Tue May 17 09:52:24 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2022-05-17 ayqdf

    感谢分享

    0